文献速递泌尿生殖与妇科肿瘤放疗

局部晚期宫颈癌患者肿瘤测量参数与鳞状细胞癌抗原变化的预后价值

Prognostic value of tumor measurement parameters and SCC-Ag changes in patients with locally-advanced cervical cancer.
PubMed 文献 · Radiat Oncol · 2022-01-10

回顾性分析2011年1月至2015年3月本院新诊断的203例IIA–IVA期宫颈鳞癌患者,接受同步放化疗,用3DSlicer计算治疗前后肿瘤直径、体积、体积缩小率及鳞状细胞癌抗原(SCC-Ag)变化。中位随访69个月,5年总生存率69.5%、无进展生存率64.5%;多因素分析显示治疗前/后肿瘤直径及治疗后SCC-Ag为总生存独立预测因子,肿瘤体积缩小率及治疗前/后SCC-Ag为无进展生存独立预测因子。

要点

  • 治疗前/后肿瘤直径及治疗后SCC-Ag是局部晚期宫颈癌总生存的独立预测因子。
  • 肿瘤体积缩小率及治疗前/后SCC-Ag与无进展生存独立相关。
  • 肿瘤测量参数与SCC-Ag呈正相关(P < 0.05)。

核心结论

  • 治疗前/后肿瘤直径、治疗前/后肿瘤体积、肿瘤体积缩小率、治疗前/后SCC-Ag及SCC-Ag下降率均为局部晚期宫颈癌的预后因素。
  • 治疗前/后肿瘤直径与治疗后SCC-Ag的预后价值最显著,肿瘤体积缩小率及治疗前/后SCC-Ag与疾病进展密切相关。
  • 作者认为尚需进一步研究肿瘤测量参数与SCC-Ag之间的相关性。

研究设计与样本

  • 回顾性研究,纳入2011年1月至2015年3月本院新诊断的203例IIA–IVA期宫颈鳞状细胞癌患者。
  • 收集临床资料与治疗前后影像信息,各参数使用3DSlicer软件计算。
  • 分析治疗前/后肿瘤直径、治疗前/后肿瘤体积、治疗前/后SCC-Ag、肿瘤体积缩小率及SCC-Ag下降率并评估其预后相关性。

主要发现

  • 中位随访69个月,5年总生存率为69.5%,5年无疾病进展生存率为64.5%。
  • 单因素分析中,治疗前/后肿瘤直径、治疗前/后肿瘤体积、肿瘤体积缩小率、治疗前/后SCC-Ag及SCC-Ag下降率与总生存和无进展生存显著相关(P < 0.05)。
  • 多因素分析中,治疗前肿瘤直径(HR = 0.373,P = 0.028)、治疗后肿瘤直径(HR = 0.376,P = 0.003)及治疗后SCC-Ag(HR = 0.374,P = 0.001)为总生存的独立预测因子。
  • 多因素分析中,肿瘤体积缩小率(HR = 2.998,P < 0.001)、治疗前SCC-Ag(HR = 0.563,P = 0.041)及治疗后SCC-Ag(HR = 0.253,P < 0.001)为无进展生存的独立预测因子。
  • 肿瘤测量参数与SCC-Ag呈正相关(P < 0.05)。

关键数值与推荐

  • 总生存独立预测因子:治疗前肿瘤直径HR = 0.373(P = 0.028)、治疗后肿瘤直径HR = 0.376(P = 0.003)、治疗后SCC-Ag HR = 0.374(P = 0.001)。
  • 无进展生存独立预测因子:肿瘤体积缩小率HR = 2.998(P < 0.001)、治疗前SCC-Ag HR = 0.563(P = 0.041)、治疗后SCC-Ag HR = 0.253(P < 0.001)。
  • 5年总生存率69.5%,5年无疾病进展生存率64.5%,中位随访69个月。

临床怎么用

  • 原文未据此给出推荐,结论为治疗前/后肿瘤直径、治疗前/后肿瘤体积、肿瘤体积缩小率、治疗前/后SCC-Ag及SCC-Ag下降率是局部晚期宫颈癌的预后因素。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To investigate the prognostic relevance of specific measurement parameters such as tumor diameter, tumor volume, tumor volume reduction rate (TVRR), and changes in the squamous cell carcinoma antigen (SCC-Ag) level in patients with locally-advanced cervical cancer (LACC) undergoing concurrent radiotherapy and chemotherapy. METHODS: This was a retrospective study of 203 patients with stage IIA-IVA cervical squamous cell carcinoma who were newly diagnosed at our hospital between January 2011 and March 2015. Clinical data and pre-and post-treatment imaging information were collected and each parameter was calculated using 3DSlicer software. The pre/post-treatment tumor diameter (TDpre/post), tumor volume (TVpre/post), SCC-Ag (SCCpre/post), and TVRR, SCC-Ag reduction rate (SCCRR) were analyzed and their prognostic relevance evaluated. RESULTS: The median follow-up was 69 months. The 5-year overall survival (OS) and disease progression-free survival (PFS) rates were 69.5% and 64.5%, respectively. On univariate analysis, TDpre/post, TVpre/post, TVRR, SCCpre/post and SCCRR showed significant association with OS and PFS (P < 0.05). On multivariate analysis, TDpre [Hazard ratio (HR) = 0.373, P = 0.028], TDpost (HR = 0.376, P = 0.003) and SCCpost (HR = 0.374, P = 0.001) were independent predictors of OS. TVRR (HR = 2.998, P < 0.001), SCCpre (HR = 0.563, P = 0.041), and SCCpost (HR = 0.253, P < 0.001) were independent predictors of PFS. Tumor measurement parameters showed a positive correlation with SCC-Ag (P < 0.05). CONCLUSION: TDpre/post, TVpre/post, TVRR, SCCpre/post, and SCCRR were prognostic factors in LACC. TDpre/post and SCCpost showed the most significant prognostic value. TVRR and SCCpre/post were closely related to disease progression. Further studies should investigate the correlation between measurement parameters of tumor and SCC-Ag.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Chen W, Xiu S, Xie X, et al. Prognostic value of tumor measurement parameters and SCC-Ag changes in patients with locally-advanced cervical cancer. Radiat Oncol. 2022. PMID: 35012582. doi:10.1186/s13014-021-01978-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。